Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF‐α pathway

Su, Shan; Dou, Hong-tao; Wang, Zhe; Zhang, Qinghua

doi:10.1111/bcpt.13487

Cited by 18 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, it was mentioned that HIF-1α is activated in hypoxic conditions and can promote cancer progression [294][295][296][297][298][299]. As there is a close relationship between HIF-1α and cancer metabolism, targeting this molecular pathway is of importance in CP sensitivity.…”

Section: Gene Therapymentioning

confidence: 99%

Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies

et al. 2021

View full text Add to dashboard Cite

The failure of chemotherapy is a major challenge nowadays, and in order to ensure effective treatment of cancer patients, it is of great importance to reveal the molecular pathways and mechanisms involved in chemoresistance. Cisplatin (CP) is a platinum-containing drug with anti-tumor activity against different cancers in both pre-clinical and clinical studies. However, drug resistance has restricted its potential in the treatment of cancer patients. CP can promote levels of free radicals, particularly reactive oxygen species (ROS) to induce cell death. Due to the double-edged sword role of ROS in cancer as a pro-survival or pro-death mechanism, ROS can result in CP resistance. In the present review, association of ROS with CP sensitivity/resistance is discussed, and in particular, how molecular pathways, both upstream and downstream targets, can affect the response of cancer cells to CP chemotherapy. Furthermore, anti-tumor compounds, such as curcumin, emodin, chloroquine that regulate ROS and related molecular pathways in increasing CP sensitivity are described. Nanoparticles can provide co-delivery of CP with anti-tumor agents and by mediating photodynamic therapy, and induce ROS overgeneration to trigger CP sensitivity. Genetic tools, such as small interfering RNA (siRNA) can down-regulate molecular pathways such as HIF-1α and Nrf2 to promote ROS levels, leading to CP sensitivity. Considering the relationship between ROS and CP chemotherapy, and translating these findings to clinic can pave the way for effective treatment of cancer patients.

show abstract

Section: Gene Therapymentioning

confidence: 99%

Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A study by Su et al published in 2020 demonstrated its usefulness in ovarian cancer, where it acted as a potent inhibitor of cell growth and migration in ovarian cancer cells through the suppression of mTOR activation and hypoxia-inducible factor 1-alpha (HIF1α) induction. The authors concluded that bufalin might be used as an additive to cisplatin in ovarian cancer therapy [ 258 ]. Lastly, tetramethylpyrazine (also named ligustrazine) is a chemical compound classified as an alkylpyrazine found in fermented soybeans and cocoa beans [ 259 ].…”

Section: Gynecological Cancersmentioning

confidence: 99%

Nutrition in Gynecological Diseases: Current Perspectives

et al. 2021

View full text Add to dashboard Cite

Diet and nutrition are fundamental in maintaining the general health of populations, including women’s health. Health status can be affected by nutrient deficiency and vice versa. Gene–nutrient interactions are important contributors to health management and disease prevention. Nutrition can alter gene expression, as well as the susceptibility to diseases, including cancer, through several mechanisms. Gynecological diseases in general are diseases involving the female reproductive system and include benign and malignant tumors, infections, and endocrine diseases. Benign diseases such as uterine fibroids and endometriosis are common, with a negative impact on women’s quality of life, while malignant tumors are among the most common cause of death in the recent years. In this comprehensive review article, a bibliographic search was performed for retrieving information about nutrients and how their deficiencies can be associated with gynecological diseases, namely polycystic ovary syndrome, infertility, uterine fibroids, endometriosis, dysmenorrhea, and infections, as well as cervical, endometrial, and ovarian cancers. Moreover, we discussed the potential beneficial impact of promising natural compounds and dietary supplements on alleviating these significant diseases.

show abstract

“…243). The PI3 K/Akt and mammalian target of rapamycin (mTOR)/HIF-1 α are other molecular pathways down-regulated by bufalin in cancer therapy (Refs 244, 245). In glioma cells, bufalin significantly promotes expression of miRNA-203 as a tumour-suppressing factor.…”

Section: Micrornas and Sox2mentioning

confidence: 99%

MicroRNAs regulating SOX2 in cancer progression and therapy response

Mirzaei

Saebfar²,

Gholami

et al. 2021

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

The proliferation, metastasis and therapy response of tumour cells are tightly regulated by interaction among various signalling networks. The microRNAs (miRNAs) can bind to 3′-UTR of mRNA and down-regulate expression of target gene. The miRNAs target various molecular pathways in regulating biological events such as apoptosis, differentiation, angiogenesis and migration. The aberrant expression of miRNAs occurs in cancers and they have both tumour-suppressor and tumour-promoting functions. On the contrary, SOX proteins are capable of binding to DNA and regulating gene expression. SOX2 is a well-known member of SOX family that its overexpression in different cancers to ensure progression and stemness. The present review focuses on modulatory impact of miRNAs on SOX2 in affecting growth, migration and therapy response of cancers. The lncRNAs and circRNAs can function as upstream mediators of miRNA/SOX2 axis in cancers. In addition, NF-κB, TNF-α and SOX17 are among other molecular pathways regulating miRNA/SOX2 axis in cancer. Noteworthy, anti-cancer compounds including bufalin and ovatodiolide are suggested to regulate miRNA/SOX2 axis in cancers. The translation of current findings to clinical course can pave the way to effective treatment of cancer patients and improve their prognosis.

show abstract

Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF‐α pathway

Cited by 18 publications

References 30 publications

Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies

Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies

Nutrition in Gynecological Diseases: Current Perspectives

MicroRNAs regulating SOX2 in cancer progression and therapy response

Contact Info

Product

Resources

About